Search

Your search keyword '"Richard D. Carano"' showing total 8 results
Start Over Author "Richard D. Carano"
8 results on '"Richard D. Carano"'

1. Supplementary Figure 2 from Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12

Author

Napoleone Ferrara, Weiru Wang, Robert F. Kelley, Camellia Adams, Richard D. Carano, Lisa A. Damico-Beyer, Wyne P. Lee, Rashi Takkar, Jenny Yao, Racquel Corpuz, Kai Barck, Eric Suto, Peter Gribling, Leah Quintana, Robyn Clark, Suzy Clark, Nancy Y. Chiang, Terence Wong, Mary Coons, Mark Ultsch, Hong Xiang, Bing Li, Jianyong Wang, and Cuiling Zhong

Abstract

PDF file, 20K, Effects of 30D8 on 4T1 cell migration in vitro.

Published
2023
Full Text
View/download PDF

2. Supplementary Figure 3 from Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12

Author

Napoleone Ferrara, Weiru Wang, Robert F. Kelley, Camellia Adams, Richard D. Carano, Lisa A. Damico-Beyer, Wyne P. Lee, Rashi Takkar, Jenny Yao, Racquel Corpuz, Kai Barck, Eric Suto, Peter Gribling, Leah Quintana, Robyn Clark, Suzy Clark, Nancy Y. Chiang, Terence Wong, Mary Coons, Mark Ultsch, Hong Xiang, Bing Li, Jianyong Wang, and Cuiling Zhong

Abstract

PDF file, 239K, Intervention studies in the laser-induced choroidal neovascularization (CNV) model.

Published
2023
Full Text
View/download PDF

3. Supplementary Figure 5 from Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12

Author

Napoleone Ferrara, Weiru Wang, Robert F. Kelley, Camellia Adams, Richard D. Carano, Lisa A. Damico-Beyer, Wyne P. Lee, Rashi Takkar, Jenny Yao, Racquel Corpuz, Kai Barck, Eric Suto, Peter Gribling, Leah Quintana, Robyn Clark, Suzy Clark, Nancy Y. Chiang, Terence Wong, Mary Coons, Mark Ultsch, Hong Xiang, Bing Li, Jianyong Wang, and Cuiling Zhong

Abstract

PDF file, 28K, Effects of 30D8 on CXCL12 and VEGF serum levels in HM7 tumor bearing mice.

Published
2023
Full Text
View/download PDF

4. Supplementary Figure Legends from Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12

Author

Napoleone Ferrara, Weiru Wang, Robert F. Kelley, Camellia Adams, Richard D. Carano, Lisa A. Damico-Beyer, Wyne P. Lee, Rashi Takkar, Jenny Yao, Racquel Corpuz, Kai Barck, Eric Suto, Peter Gribling, Leah Quintana, Robyn Clark, Suzy Clark, Nancy Y. Chiang, Terence Wong, Mary Coons, Mark Ultsch, Hong Xiang, Bing Li, Jianyong Wang, and Cuiling Zhong

Abstract

PDF file, 78K

Published
2023
Full Text
View/download PDF

5. Supplementary Figure 1 from Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12

Author

Napoleone Ferrara, Weiru Wang, Robert F. Kelley, Camellia Adams, Richard D. Carano, Lisa A. Damico-Beyer, Wyne P. Lee, Rashi Takkar, Jenny Yao, Racquel Corpuz, Kai Barck, Eric Suto, Peter Gribling, Leah Quintana, Robyn Clark, Suzy Clark, Nancy Y. Chiang, Terence Wong, Mary Coons, Mark Ultsch, Hong Xiang, Bing Li, Jianyong Wang, and Cuiling Zhong

Abstract

PDF file, 869K, Proliferation and apoptosis analysis by IF staining in EL4 tumor sections.

Published
2023
Full Text
View/download PDF

6. Supplementary Figure 6 from Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12

Author

Napoleone Ferrara, Weiru Wang, Robert F. Kelley, Camellia Adams, Richard D. Carano, Lisa A. Damico-Beyer, Wyne P. Lee, Rashi Takkar, Jenny Yao, Racquel Corpuz, Kai Barck, Eric Suto, Peter Gribling, Leah Quintana, Robyn Clark, Suzy Clark, Nancy Y. Chiang, Terence Wong, Mary Coons, Mark Ultsch, Hong Xiang, Bing Li, Jianyong Wang, and Cuiling Zhong

Abstract

PDF file, 26K, Comparison of PK in Balb c/nude mice of three hamster antibodies with similar binding affinity toward human CXCL12.

Published
2023
Full Text
View/download PDF

7. Supplementary Figure 4 from Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12

Author

Napoleone Ferrara, Weiru Wang, Robert F. Kelley, Camellia Adams, Richard D. Carano, Lisa A. Damico-Beyer, Wyne P. Lee, Rashi Takkar, Jenny Yao, Racquel Corpuz, Kai Barck, Eric Suto, Peter Gribling, Leah Quintana, Robyn Clark, Suzy Clark, Nancy Y. Chiang, Terence Wong, Mary Coons, Mark Ultsch, Hong Xiang, Bing Li, Jianyong Wang, and Cuiling Zhong

Abstract

PDF file, 38K, Sequence alignment of 30D8 and humanized 30D8 (hu30D8).

Published
2023
Full Text
View/download PDF

8. Data from Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12

Author

Napoleone Ferrara, Weiru Wang, Robert F. Kelley, Camellia Adams, Richard D. Carano, Lisa A. Damico-Beyer, Wyne P. Lee, Rashi Takkar, Jenny Yao, Racquel Corpuz, Kai Barck, Eric Suto, Peter Gribling, Leah Quintana, Robyn Clark, Suzy Clark, Nancy Y. Chiang, Terence Wong, Mary Coons, Mark Ultsch, Hong Xiang, Bing Li, Jianyong Wang, and Cuiling Zhong

Abstract

Purpose: Our goal was to develop a potent humanized antibody against mouse/human CXCL12. This report summarized its in vitro and in vivo activities.Experimental Design: Cell surface binding and cell migration assays were used to select neutralizing hamster antibodies, followed by testing in several animal models. Monoclonal antibody (mAb) 30D8 was selected for humanization based on its in vitro and in vivo activities.Results: 30D8, a hamster antibody against mouse and human CXCL12α, CXCL12β, and CXCL12γ, was shown to dose-dependently block CXCL12α binding to CXCR4 and CXCR7, and CXCL12α-induced Jurkat cell migration in vitro. Inhibition of primary tumor growth and/or metastasis was observed in several models. 30D8 alone significantly ameliorated arthritis in a mouse collagen-induced arthritis model (CIA). Combination with a TNF-α antagonist was additive. In addition, 30D8 inhibited 50% of laser-induced choroidal neovascularization (CNV) in mice. Humanized 30D8 (hu30D8) showed similar in vitro and in vivo activities as the parental hamster antibody. A crystal structure of the hu30D8 Fab/CXCL12α complex in combination with mutational analysis revealed a “hot spot” around residues Asn44/Asn45 of CXCL12α and part of the RFFESH region required for CXCL12α binding to CXCR4 and CXCR7. Finally, hu30D8 exhibited fast clearance in cynomolgus monkeys but not in rats.Conclusion: CXCL12 is an attractive target for treatment of cancer and inflammation-related diseases; hu30D8 is suitable for testing this hypothesis in humans. Clin Cancer Res; 19(16); 4433–45. ©2013 AACR.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results